+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Restenosis (Cardiovascular) - Drugs In Development, 2021

  • ID: 5359602
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 40 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • CytoTools AG
  • VasThera Co Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Restenosis (Cardiovascular) - Drugs In Development, 2021, provides an overview of the Restenosis (Cardiovascular) pipeline landscape.

Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Restenosis (Cardiovascular) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Restenosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restenosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Restenosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restenosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Restenosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restenosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restenosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restenosis (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restenosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restenosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • CytoTools AG
  • VasThera Co Ltd
Introduction
  • Report Coverage
Restenosis - Overview

Restenosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Restenosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Restenosis - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Co
  • CytoTools AG
  • VasThera Co Ltd
Restenosis - Drug Profiles

(connective tissue growth factor + insulin human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
apixaban - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
HMW-02Ak - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
HMW-02Ap - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
TW-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
VTA-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Restenosis - Dormant Projects

Restenosis - Discontinued Products

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Restenosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Restenosis - Pipeline by Bristol-Myers Squibb Co, 2021
  • Restenosis - Pipeline by CytoTools AG, 2021
  • Restenosis - Pipeline by VasThera Co Ltd, 2021
  • Restenosis - Dormant Projects, 2021
  • Restenosis - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Restenosis, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Bristol-Myers Squibb Co
  • CytoTools AG
  • VasThera Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll